

Curasight Q2 - Strategic progress

Redeye updates its view of Curasight following the Q2 report and recent events in the company, including an announced financing solution and progress with uTRACE in prostate cancer.

Read more and download the Research Update.

Follow companies at Redeye to receive the latest equity research within Life Science and Technology.

This is a press release from Redeye - Research Powered Investment Banking. www.redeye.se/

Attachments

Curasight Q2 - Strategic progress